RE: Hemogenyx16 Jun 2022 10:39
The horse analogy was started long ago and holds true and I think its very apt, we have a great jockey in Vlad who has shown incredible discipline in resource management and managed to produce CAR-T, CBR, CDX and Hu-PHEC to the point where they are patent protected and atleast 2 of these quickly approaching Clinical status. The horse is the science, IE CAR-T and it fits the analogy REALLY WELL because as a pre-clinical thoroughbred it has no handicap yet, Vlad knows how well it performs but its yet to be on the national sheets. And for the racecourse? It been specially chosen for this particular horse, a subset of AML with high demand and no current cure, a perfect target which can come with it the benifit of fast track from the FDA(Excuse that pun).
I stopped using the horse race anology because although it was apt and fitting, it was getting annoying, this is a serious company doing serious work to save lives and I felt carrying on with the horse/donkey rubbish detracts from the science.
So to your point, you have stated in your own words you expect GOG to out perform HEMO, you said that on the HEMO board. You did not use as few words but when you tell people that your currently invested elsewhere and you will sell those shares at a profit in a few weeks to buy HERE at this exact price your basically saying "GOG will make lots of profit in the next few weeks, HEMO will not"
Which to be fair if you were talking about an oiler with expected drill results, or perhaps some company with expected contract to be announced I would shrug my shoulders and say work away. But on first glance it looks like GOG may very well be subject to a takeover which is great and all..... But your missing the great big obvious elephant in the room. IF that happens your shares are suspended, you do understand that right?